Metabiomics
Press Releases
FDA Grants Breakthrough Designation to the Prescient Metabiomics LifeKit® Prevent Test for the Early Detection of Colon Polyps and Colon Cancer
CARLSBAD, Calif., Sept. 4, 2019 /PRNewswire/ -- Prescient Metabiomics, a privately held company and a subsidiary of Prescient Medicine Holdings, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted the company's submission for...
Prescient Medicine and Metabiomics Partner to Develop New Gastrointestinal Health Tests to Detect Polyps, Prevent Colon Cancer
Prescient Medicine Holdings, LLC and Metabiomics Corp., have announced a joint venture to develop an innovative microbiome diagnostics platform for detecting precancerous colon polyps and diagnosing other types of gastrointestinal diseases including Crohn’s, colitis (IBD), and irritable bowel syndrome (IBS).
Metabiomics Featured in BiopharmaDIVE
In a recent article by Suzanne Elvidge, published in BiopharmaDIVE, Metabiomics was highlighted as a clinical development leader that is exploring the links between microbiota and colon cancer.
Metabiomics Concludes Colorectal Polyp Study with 232 Subjects Enrolled
Metabiomics is proud to announce the completion of one of the largest case-controlled studies on the colorectal polyp microbiome.
Origin Sciences and Metabiomics Announce Exclusive Distribution Agreement of OriCol™ Microbiome Sampling Kits in the U.S.
PRESS RELEASE Cambridge, UK and Aurora, CO December 16, 2015 Metabiomics Corp. announced it has secured a distribution agreement with Origin Sciences pursuant to which it will develop, test, and commercialize the novel OriCol™ gastrointestinal sampling technology for...
Microbiome R&D and Business Collaboration Forum
San Diego, CA September 10, 2015 Metabiomics is pleased to be attending the 3rd annual Global Engage Microbiome R&D and Business Collaboraton Forum. Greg Kuehn, President and COO will be giving a talk on Day 2 (sept 11) covering the company's...
Metabiomics Expands Clinical Research Team and Advisory Board
Metabiomics expands management team and advisory board to include Dr. Louis Korman, Dr. Robert Hardi, Dr. Jeffrey Baybick and Dr. Paul DeRidder. The new team members have extensive clinical research, healthcare, gastroenterology, pathology and international business development experience.
David Hanzel joins Metabiomics as President and COO
Metabiomics is pleased to announce the addition of a new key member to our management team. Dr. David Hanzel has joined Metabiomics as our President and Chief Operating Officer.
Metabiomics to Present Colorectal Cancer Screening Test at Upcoming Investor Conference, OneMedForumNY 2013
Metabiomics, an early stage microbiome diagnostics company, will be presenting an investment opportunity next week at OneMedForumNY in New York.